54643-09-3 Usage
Uses
Used in Pharmaceutical Industry:
1-Propanone, 1-(2-pyrimidinyl)(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique structure and properties make it a valuable building block in the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
1-Propanone, 1-(2-pyrimidinyl)(9CI) is utilized in medicinal chemistry for its potential applications in the discovery and design of novel therapeutic agents. Its unique chemical properties and reactivity enable the development of new compounds with improved pharmacological profiles and therapeutic effects.
Used in Research and Development:
1-Propanone, 1-(2-pyrimidinyl)(9CI) is primarily employed in research and development activities within the pharmaceutical industry. It serves as a crucial component in the synthesis and evaluation of new drug candidates, contributing to the advancement of pharmaceutical science and the development of innovative treatments for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 54643-09-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,6,4 and 3 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 54643-09:
(7*5)+(6*4)+(5*6)+(4*4)+(3*3)+(2*0)+(1*9)=123
123 % 10 = 3
So 54643-09-3 is a valid CAS Registry Number.
54643-09-3Relevant academic research and scientific papers
SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
-
Paragraph 00182; page 71, (2014/08/19)
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
-
Paragraph 00123; 00133, (2014/08/19)
Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
